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Background: The use of contrast medium for percutaneous coronary intervention leads to an increased rate of contrast induced nephropathy 
(CIN) in diabetic patients with renal failure.
Iodixanol 320, an iso-osmolar, nonionic contrast medium (IOCM) may reduce the risk of CIN compared to use of low-osmolar, nonionic contrast 
medium (LOCM) such as Iomeprol 350.
The purpose of the CONTRAST trial (COntrast media and NephroToxicity following coronary Revascularization by AngioplaSTy) was to compare the 
nephrotoxic effect of Iodixanol 320 and Iomeprol 350 in 975 diabetic and non-diabetic patients with impared renal function undergoing coronary 
angiography (CAG) with or without percutaneous coronary intervention (PCI). The aim was to assess the outcomes of a subset of 319 diabetic 
patients randomly assigned to either Iodixanol 320 or Iomeprol 350.
Methods: A prospective, randomized, double blind, comparative clinical trial was performed in two university heart centers. Diabetic patients with 
impaired renal function (MDRD calculated glomerular filtration rate ≤ 60 ml/min and/or S-creatinine ≥ 1.5 mg/dl) were randomized to receive 
either Iodixanol 320 or Iomeprol 350. Patients received continuous i.v. hydration therapy with 0.9% sodium chloride. Primary endpoint was the peak 
increase in S-creatinine during index hospitalization. Secondary endpoints were cardiovascular adverse events.
Results: The cohort contained 38% insulin-dependent diabetics and 81% patients with multi-vessel disease. There were 159 patients receiving 
iodixanol and 160 patients receiveing iomeprol. Baseline GFR was 46 ± 11 ml/min in the IOCM group and 47 ± 11 ml/min in the LOCM group. CIN 
occurred in approx. 20% in both groups. The mean change of S-creatinine was not significantly different between the groups and amounted to 0.18 
± 0.38 mg/dl in the iodixanol group and 0.14 ± 0.40 mg/dl in the iomeprol group (P=0.39).
Conclusions: The results obtained from this largest series of diabetic patients with impaired renal function randomly assigned to two different 
contrast media show that the iso-osmolar contrast medium iodixanol does not reduce nephrotoxicity after coronary angiography with or without 
subsequent PCI.
